Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.44 |
| ▸ | PIM1 | P11309 | 8/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14724362 | 0.90 | MET (0.44) | METPIM1MKNK1FLT3GSK3B | |
| SCHEMBL1133887 | 0.82 | CYP1A2 (0.43) | METPIM1CDK2NQO2PDE3B | |
| SCHEMBL12224213 | 0.81 | LRRK2 (0.53) | METPIM1CDK2NQO2PDE3B | |
| SCHEMBL12224216 | 0.79 | PIM1 (0.43) | METPIM1CDK2NQO2PDE3B | |
| SCHEMBL2452345 | 0.79 | DYRK3 (0.53) | METCDK2NQO2PDE3BPDE3A | |
| SCHEMBL1133729 | 0.76 | MET (0.45) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133683 | 0.76 | MET (0.62) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133888 | 0.72 | CYP1A2 (0.43) | METPIM1FLT3GSK3BCDK2 | |
| SCHEMBL1133840 | 0.67 | PIM1 (0.43) | METPIM1NQO2PDE3BPDE3A | |
| SCHEMBL14138195 | 0.66 | MET (0.62) | METNQO2PDE3BPDE3APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426397-B2 | 3 (3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-04-23 | — | — | US | disclosed |
| EP-2367827-B1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4]TRIAZOLO [4,3-b]PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | MERCK PATENT GMBH MIT BESCHRAENKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| WO-2010072301-A1 | 3-(3-PYRIMIDINE-2-YL-BENZYL)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257173-A1 | 3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives | RET, ERBB2, JAK2 | MET 5/4885PIM1 44/4885MKNK1 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.